Evidence map›Paper›PMID 34715052›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2022

Emerging nanotechnologies in cardiovascular medicine.

Alessandro Grattoni, John P Cooke

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alessandro GrattoniDepartment of Nanomedicine, Houston Methodist Research Institute; Department of Surgery, Houston Methodist Hospital; Department of Radiation Oncology, Houston Methodist Hospital. Electronic address: agrattoni@houstonmethodist.org.
John P CookeDepartment of Cardiovascular Sciences, Center for Cardiovascular Regeneration, Houston Methodist Research Institute; Center for RNA Therapeutics, Houston Methodist Hospital, Houston, TX, USA.

Funding

Reversal of Heart Failure: Role of Vascular RecoveryR01HL148338 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU, COOKE, JOHN P · 2020 to 2023
$2.8M
Role of S-nitrosylation in TransdifferentiationR01HL133254 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU, COOKE, JOHN P · 2018 to 2021
$1.6M
A nanofluidic platform for tunable drug deliveryR01GM127558 · NIGMS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI GRATTONI, ALESSANDRO, LIU, XUEWU · 2018 to 2021
$1.6M
Computational epigenetics modeling of cell identity genesR01GM125632 · NIGMS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU · 2018 to 2021
$1.4M
NHLBI NIH HHS R01 HL133254NHLBI NIH HHS R01 HL148338NIGMS NIH HHS R01 GM125632NIGMS NIH HHS R01 GM127558
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug Delivery SystemsNanotechnologyCardiovascular diseasesDrug deliveryInnovative therapeuticsNanotechnology

Identifiers

PMID34715052
PMCPMC8884449

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.